Japan Statute Of Limitations Limit Novartis Exposure In Diovan Scandal
This article was originally published in PharmAsia News
Executive Summary
Novartis Pharma K.K. may be absolved of some of the allegations it engaged in false advertising when it cited results from clinical trials of its Diovan (valsartan).